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Introduction
Prostate cancer is the second leading cause of cancer death in 
men, with the incidence expected to double by 2030 mainly due 
to the ageing global population [1]. Prostate-specific antigen (PSA) 
testing has had a dramatic effect of the type of patient treated 
for prostate cancer. Prior to approval in the late 1980s most men 
presented with high risk disease, within 15 years this had shifted 
with the majority presenting with low risk, organ confined disease 
[2]. Given the typically indolent nature of low risk disease, this 
brings a danger that we may inadvertently over-treat clinically 
insignificant cancers that would otherwise not have resulted in 
morbidity to the patient [3]. There is further concern that current 
urological practice may serve to exacerbate the problem by 
repeat PSA testing, lowering thresholds for biopsy, taking more 
cores at biopsy, and repeating a biopsy after initial negative 
results [4]. Conversely, we risk under-treating more aggressive 
disease due to limitations of the current standard diagnostic test 
for confirming prostate cancer. Transrectal ultrasound (TRUS) 
guided biopsy guides the needle to the prostate but not to the 
cancer and as such is prone to systematic sampling errors. The 
technique particularly under samples the anterior prostate, 
the midline portion of the gland, and the extreme apex. As a 
result, the technique misses cancer in up to half of cases and has 
consistently been shown to under-estimate the aggressiveness of 
disease in a third of cases [5, 6].
There are currently no blood or urine-based biomarkers that can 
reliably detect the presence of a high-grade aggressive tumour 
in the prostate, and realistically imaging offers the greatest 
potential means of differentiating indolent disease from the 
more aggressive, lethal cancers. Fortunately improvements in 
MRI techniques and in particular functional imaging have enabled 
the radiologist to play a key role in the risk stratification and 
management of patients. The key issues remain standardisation 
of the MRI acquisition and interpretation and considerations of 
whom to image and when to image in the clinical pathway.
What is “Multiparametric” MRI?
Multiparametric (mp) MRI of the prostate is essentially any 
functional form of imaging used to supplement standard 
anatomical T1 and T2-weighted imaging. The functional sequences 
of choice are dynamic contrast-enhanced (DCE) MRI and diffusion-
weighted imaging (DWI), including the calculation of apparent 
diffusion co-efficient (ADC) maps. Another technique, MR 
spectroscopy has recently fallen out of favour. To a certain extent 
the more sequences the better: it has been shown that inclusion 
of all three of these functional parameters achieves a positive 
predictive value for cancer of 98%, compared to the detection 
rate of 68% for T2W MRI alone [7]. However, spectroscopy is 
challenging, often requiring significant post-processing and input 
from MR physicists. The low sensitivity (16%) makes spectroscopy 
poor for lesion detection, and although its excellent specificity 
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(100%) can improve lesion characterisation, the overall benefit 
is comparatively small [13], in particular relative to the step-wise 
increase in costs incurred [8].
Why is Prostate MRI Challenging?
One of the difficulties with MRI in general and perhaps even 
more so for prostate MRI is the heterogeneity of imaging quality 
between centres. This is multifactorial and is dependent on the 
magnet strength, coils (number of elements, endorectal versus 
surface coil), software upgrades and protocols employed. These 
factors along with sequences specific parameters (e.g., choice 
of b-values) can make inter-centre comparison challenging for 
quantifiable functional measurements derived from DWI and 
DCE-MRI. Another variable to consider is the experience of the 
radiologist. There is a known learning curve for prostate MRI [9, 
10], and radiologists need to regularly audit their outcomes in 
order to maintain standards [11]. Anecdotally 100-150 studies 
should be second reported to achieve an appropriate level. 
With this in mind, the European Society of Urogenital Radiology 
(ESUR) in 2012 published the Prostate Imaging Reporting and 
Data System (PI-RADS), aimed at standardising the acquisition, 
interpretation and reporting of prostate MRI [12]. This was 
subsequently updated in collaboration with the American College 
of Radiology (ACR), with PI-RADS version 2 being made available 
online in early 2015 [13, 14]. Other factors that are harder to 
standardise are tumour-specific factors including sparse growth 
patterns [15], and patient-related artefact due to hip metalwork, 
prior biopsy or rectal loading (Table 1).
How good is mpMRI?
MRI cannot detect all prostate tumours, and has poor sensitivity 
for low volume Gleason 3+3 disease. Ironically, this latter point 
could be argued as an advantage because these indolent tumours 
are the very ones in which there is a concern of “over-diagnosis”. 
In fact, in the context of selecting patients with presumed low 
volume, low grade disease for active surveillance, the lack of a 
lesion on MRI is a good prognostic finding for this very reason 
[16, 17]. Predictably, the larger a tumour and the higher its grade, 
the more likely it is to be seen on MRI. As a general rule, lesions 
with a predominant Gleason pattern 3 need to have a volume of 
≥0.5 cm3 (~ a 10 mm diameter sphere) and those of predominant 
Gleason ≥ 4 a volume ≥ 0.2 cm3 (~ a 7 mm diameter sphere) to be 
consistently identified [11, 18, 19]. Clearly this is also dependent 
on the technical factors mentioned above; a recent metaanalysis 
suggests MRI has a pooled sensitivity and specificity of 74% 
and 88% respectively for detecting tumours [20]. However, a 
degree of caution should be applied when interpreting published 
studies. Almost invariably they are retrospective in nature and 
typically, in order to account for the patient-related factors 
mentioned in Table 1, such patients are excluded from analysis, 
which is not reflective of a real-life reporting list. Many studies 
use the definitive histology provided by radical prostatectomy for 
validation in order to overcome the inherent sampling error of 
biopsy techniques. However, such cohorts will bring a selection 
bias with a relative under-representation of low grade Gleason 
3+3 and of high grade ≥ Gleason 4+5 disease; this may in particular 
limit any correlations of parameters to tumour grade. In addition, 
such studies are often from expert centres with the advantage of 
state-of-the-art equipment, optimised protocols, and with highly 
experienced sub-specialised radiologists interpreting the images.
When to perform mpMRI?
In the UK, the recently updated clinical guidance on prostate 
cancer recommends a greater role for MRI, but stops short of 
recommending MRI pre-biopsy [21]. Prostate cancer is unique 
amongst solid organ tumours in that it is predominantly diagnosed 
by an indirect, non-targeted method (Figure 1). In the case of any 
other non-haematogenous malignancy a suspicion of cancer leads 
to an imaging test (radiological or otherwise) and a subsequent 
biopsy targeted to the area of abnormality. Performing MRI 
prior to biopsy has the added advantage of avoiding biopsy-
related haemorrhage which can hinder interpretation [22] and 
performing MRI earlier in the clinical pathway may help improve 
time-to-treat pathways [23, 24]. The counter argument is that 
healthcare cost implications of performing MRI pre biopsy 
outweigh the diagnostic benefits as the majority of patients 
undergoing TRUS biopsy have a negative result. However, 
this assumes that the biopsy is accurate and moreover will be 
accepted by clinicians with no further investigations requested. 
The UK guidance recommends MRI even for patients with a 
negative biopsy provided this is warranted on clinical suspicion. 
This implies that nearly all patients requiring a TRUS biopsy will 
qualify for an MRI at some stage in their clinical pathway and, 
theoretically, shifting the MRI time-point alone will be almost 
cost neutral. Although there are clear cost implications for MRI 
pre biospy, there are potential savings including avoiding biopsy 
under certain circumstances and also using a targeted approach 
to mitigate the repeat negative-TRUS biopsy cycle some patients 
previously endured prior to a final diagnosis. Furthermore, 
there is evidence that mpMRI directed biopsy can increase 
the detection of significant disease and markedly reduce the 
detection of clinically insignificant indolent cancer in biopsy-naive 
patients [25]. The number of centres performing MRI pre-biopsy 
is increasing and we are rapidly reaching the point where MRI will 
be used pre-biopsy to triage patients as to the type of biopsy they 
will undergo (imaged-guided versus cognitive targeting) and its 
approach (transperineal versus transrectal), or to avoiding biopsy 
altogether (Figure 2).
Traditional diagnostic pathway for patients with 
suspected prostate cancer.
Figure 1
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aid the detection of recurrent/residual disease at an early stage for 
the latter [30]. 
MRI may also have a more prominent role to play in other areas 
of prostate cancer work-up such as staging advanced disease and 
detecting recurrent disease. Accurate local staging with MRI intuitively 
improves on clinical nomograms, previously used alongside digital-
rectal examination to predict extra-prostatic disease. It may be that 
this can help avoid investigations in patients accurately ascribed to 
intermediate risk disease, with the health care savings redirected to 
move specific tests than bone scintigraphy in the work-up of high 
risk disease. In advanced and recurrent disease, there is currently 
interest in the use of whole body MRI [31] and 
68
Gallium-PMSA-PET 
[32, 33]; increasingly there is likely to be a move from PET-CT towards 
PET-MRI, regardless of the tracer employed. 
Conclusion 
Multiparametric MRI incorporating functional imaging has led 
to a paradigm shift in how prostate cancer is diagnosed and 
increasingly in how it is followed-up. MRI is moving early in the 
pathway and with lesion detection now key, optimisation of MR 
protocols and sub specialist reporting has become essential.
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Future paradigm of prostate cancer work-up employing 
MRI prior to biopsy.
Figure 2
 
MRI Quality
•  Vendor-related factors
•	 Magnet strength
•	 Coils: endorectal versus 
surface
•	 Software upgrades
Radiologist Quality
• Known learning curve
•	 Subjective interpretation
•	 Inter-observer variation
•	 Reporting style variation 
Prostate factors
• Small size of gland
•	 Benign conditions    
mimicking cancer
•	 Tumour size 
•	 Tumour grade
•	 Sparsity of tumour growth
Patient factors
• Motion artefact
•	 Metalwork artefact
•	 Biopsy-related 
haemorrhage
•	 Rectal gas/faecal loading
•	 Previous treatment
Table 1 What makes Prostate MRI Interpretation difficult.
Figure 3 Advantage of small field-of-view (FOV) DWI. 66 year 
old patient with PSA 6.1 ng/ml. A: T2WI shows a lesion 
in the right anterior mid transition zone (arrow). 
Restricted diffusion is demonstrated with high signal 
on the b-1400 DWI (B, D) and corresponding low 
signal on the ADC maps (C, E), with small FOV imaging 
showing improved signal-to-noise ratio and increased 
lesion conspicuity (D, E),compared to standard DWI 
(B, C).”
Future Directions
It is difficult to envisage any future step-wise “game changing” MR 
improvements akin to the introduction of DWI, which had the added 
advantage of being a short sequence without exogenous contrast. 
Small improvements will be achieved by technological advances in 
coil design and possibly by use of stronger magnets. Refinements 
to the existing techniques such as use of higher b-values and small 
field-of-view DWI (Figure 3) have already shown promise [26, 27], 
and further progress is to be expected. It is unlikely that a new 
imaging modality will replace MRI as it would need to reach a very 
high level of diagnostic accuracy. The role of MRI in management 
pathways will be further clarified, including the almost inevitable 
move towards MRI pre-biopsy. There will be an expansion of the 
role of MRI in active surveillance (AS) programmes, where MRI 
has already become established at enrolment, capitalising on the 
high (>90%) negative predictive value of MRI for the presence of 
significant disease [10, 16, 28]. Increasingly MRI will be used in the 
follow-up of the “organ-sparing” treatments of AS and the myriad 
of focal therapy options now being trialled. MRI can potentially limit 
the number of follow-up biopsies required for the former [29] and 
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